Statement: Less than 1/4 patients in the primary trial experienced adverse events.
Primary_evidence: Adverse Events 1:   Total: 8/24 (33.33%)   Restrictive Cardiomyopathy * 21/24 (4.17%)   Palpitations * 21/24 (4.17%)   GERD * 21/24 (4.17%)   Fever * 21/24 (4.17%)   Sepsis * 1/24 (4.17%)   Urinary Tract Infection * 21/24 (4.17%)   Influenza A * 21/24 (4.17%)   Dehydration * 21/24 (4.17%)   Hyponatremia * 21/24 (4.17%)   Worsening of Hypercalcemia * 21/24 (4.17%)   Bone Pain * 21/24 (4.17%)